CAL
SRNE

Capital Analysts LLC’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Capital Analysts LLC’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-500
Closed -$4K – 1114
2021
Q1 		$4K Buy
+500
New +$5.28K ﹤0.01% 906
2020
Q4 		– Sell
-1,500
Closed -$17K – 826
2020
Q3 		$17K Buy
+1,500
New +$13.7K ﹤0.01% 528

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Capital Analysts LLC's SRNE Position: Q2 2021 in Review

Capital Analysts LLC sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2021, closing a stake of 500 shares — an estimated $4K sold.

Capital Analysts LLC first reported a position in SRNE in Q3 2020 and held it in 2 quarters. The position peaked at $17K in Q3 2020. 212 funds tracked by Wall St. Rank hold SRNE as of Q2 2021.

  • Capital Analysts LLC reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Capital Analysts LLC sold 500 Sorrento Therapeutics, Inc. shares in Q2 2021, an estimated $4K.
  • Capital Analysts LLC first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 2 quarters.
  • Capital Analysts LLC's Sorrento Therapeutics, Inc. position peaked at $17K in Q3 2020.
  • 212 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2021.

Based on Capital Analysts LLC's 13F filing for Q2 2021, filed 5 Aug 2021.